In the study, 90 male outpatients (mean age, 45 years) with major depression in remission and sexual dysfunction associated with SSRI antidepressant treatment were randomised to sildenafil (n = 45) or placebo (n = 45) at a flexible dose starting at 50 mg and adjustable to 100 mg before sexual activity for 6 weeks.
The primary outcome measure was score on the Clinical Global Impression-Sexual Function (CGI-SF); secondary measures were scores on the International Index of Erectile Function, Arizona Sexual Experience Scale, Massachusetts General Hospital-Sexual Functioning Questionnaire, and Hamilton Rating Scale for Depression (HAM-D).
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!